Pharmena S.A. engages in the sale of dietary supplements in Poland and internationally. The company also develops 1-MNA (PHR-701 program), a medical device for use in difficult-to-heal wounds. In addition, it is involved in research and development of therapeutic applications of 1 MNA as an anti-inflammatory and anti-fibrotic drug; and research and development at pulmonary fibrosis, respiratory tract infections, including viral infections, COVID-19, inflammatory diseases, metabolic diseases and other therapeutic applications. The company was incorporated in 2002 and is based in Lódz, Poland. Pharmena S.A. is a subsidiary of Pelion S.A.
Research context
PHR appears in PyInvesting’s Warsaw Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- PLN
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
No comments yet
Start a focused discussion about PHR.WAR.